A population pharmacokinetics analysis assessing the exposure of raltegravir once‐daily 1200 mg in pregnant women living with HIV

Once‐daily two 600 mg tablets (1200 mg q.d.) raltegravir offers an easier treatment option compared to the twice‐daily regimen of one 400 mg tablet. No pharmacokinetic, efficacy, or safety data of the 1200 mg q.d. regimen have been reported in pregnant women to date as it is challenging to collect t...

Descripción completa

Detalles Bibliográficos
Autores principales: Bukkems, Vera E., Post, Teun M., Colbers, Angela P., Burger, David M., Svensson, Elin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894397/
https://www.ncbi.nlm.nih.gov/pubmed/33369217
http://dx.doi.org/10.1002/psp4.12586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894397/
https://www.ncbi.nlm.nih.gov/pubmed/33369217
http://dx.doi.org/10.1002/psp4.12586

Ejemplares similares